国际眼科纵览 ›› 2025, Vol. 49 ›› Issue (2): 129-134.doi: 10.3760/cma.j.cn115500-20241010-25209

• 综述 • 上一篇    下一篇

病理性近视继发脉络膜新生血管形成的机制与治疗

叶红莉  高云安  喻圣斌   

  1. 川北医学院附属三台医院眼科,四川绵阳 621100
  • 收稿日期:2024-10-10 出版日期:2025-04-22 发布日期:2025-04-10
  • 通讯作者: 喻圣斌,Email:21814649@qq.com

Pathogenesis and treatment of choroidal neovascularization secondary to pathological myopia

Ye Hongli, Gao Yunan, Yu Shengbin   

  1. Department of Ophthalmology, Santai Hospital Affiliated to North Sichuan Medical College, Mianyang Sichuan 621100, China
  • Received:2024-10-10 Online:2025-04-22 Published:2025-04-10
  • Contact: Yu Shengbin, Email: 21814649@qq.com

摘要: 病理性近视脉络膜新生血管形成(pathological myopia-induced choroidal neovascularization,PM-CNV)可严重导致不可逆中心视力丧失,影响患者的生活质量,其发生与眼轴过长导致的视网膜脉络膜机械牵拉、血流动力学异常以及遗传因素综合作用相关。目前抗VEGF药物治疗已成为PM-CNV的标准一线治疗方法,但其长期疗效欠佳,且多次给药存在视网膜脉络膜萎缩变薄风险。目前,一些更为强效、持久治疗PM-CNV的新药正在进行研究与临床试验。(国际眼科纵览,2025, 49:129-134

关键词: 病理性近视, 脉络膜新生血管形成

Abstract: Pathological myopia-induced choroidal neovascularization (PM-CNV) can severely lead to irreversible central vision loss, affecting the quality of life of patients. Its onset is related to the combined effects of mechanical traction on the retina and choroid caused by excessive axial length, abnormal hemodynamics, and genetic factors. Currently, anti-VEGF drugs have become the standard first-line treatment for PM-CNV, but their long-term efficacy is not satisfactory, and repeated administration poses a risk of retinal and choroidal atrophy and thinning. Currently, some new drugs with stronger and more lasting effects for PM-CNV are undergoing basic research and clinical trials.(Int Rev Ophthalmol, 2025, 49:  129-134)

Key words: pathological myopia, choroidal neovascularization